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Background: Resistance to apoptosis is a major problem in ovarian cancer (OC) and correlates with poor prognosis.
Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-κB
ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). OPG has been reported to
attenuate TRAIL-induced apoptosis in a variety of cancer cells, including OC cells. OPG-mediated protection against
TRAIL has been attributed to its decoy receptor function. However, OPG activates integrin/focal adhesion kinase
(FAK) signaling in endothelial cells. In OC cells, activation of integrin/FAK signaling inhibits TRAIL-induced apoptosis.
Based on these observations, we hypothesized that OPG could attenuate TRAIL-induced apoptosis in OC cells
through integrin/FAK signaling.
Methods: In vitro experiments including immunoblots, colony formation assays, and apoptosis measurements were
used to assess the effect of OPG on TRAIL-induced apoptosis.
Results: Exogenous OPG protected from TRAIL-induced apoptosis in a TRAIL binding-independent manner and
OPG protection was αvβ3 and αvβ5 integrin/FAK signaling-dependent. Moreover, OPG-mediated activation of
integrin/FAK signaling resulted in the activation of Akt. Inhibition of both integrin/FAK and Akt signaling significantly
inhibited OPG-mediated attenuation of TRAIL-induced apoptosis. Although OPG also stimulated ERK1/2
phosphorylation, inhibition of ERK1/2 signaling did not significantly altered OPG protection.
Conclusions: Our studies provide evidence, for the first time, that OPG can attenuate TRAIL-induced apoptosis in a
TRAIL binding-independent manner through the activation of integrin/FAK/Akt signaling in OC cells.
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Osteoprotogerin (OPG) is a secreted member of the
TNF receptor superfamily that was originally character-
ized based on its ability to suppress osteoclast formation
[1,2]. OPG binds to the receptor activator of NF-κB lig-
and (RANKL) and functions as a soluble decoy receptor
for RANKL. In bone, OPG inhibits osteoclastogenesis by
preventing RANKL from binding to its receptor RANK
and, consequently promotes apoptosis of osteoclast [1].* Correspondence: alain.piche@usherbrooke.ca
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stated.OPG is critical for osteoclastogenesis and, therefore,
homeostasis of bone remodeling and bone mass [3]. In
addition to its role in bone metabolism, OPG has been
implicated in mucosal immunity [4] and vascular systems.
OPG is secreted by endothelial cells [5,6] and promotes
both proliferation and migration of microvascular endothe-
lial cells [7,8], and induces angiogenesis [8-10]. OPG can
also serve as survival factor for endothelial cells [6,8].
Furthermore, OPG acts as a decoy receptor of TNF-related
apoptosis-inducing ligand (TRAIL) and neutralizes its func-
tion [11,12]. TRAIL belongs to the TNF family of cytokines
and has emerged as a promising anticancer agent because
of its ability to selectively induce apoptosis in a broad hostd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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(TRAIL-R1 and TRAIL-R2) initiates the extrinsic pathway
of apoptosis, resulting in recruitment of the adapter protein
Fas-associated death domain (FADD) and procaspase-8 in
the death inducing signaling complex (DISC). Caspase-8
can directly activate the effector caspases (caspase‐3, ‐6, ‐7)
leading to the execution of apoptosis [14]. However, in
ovarian cancer cells, the apoptotic signal must be further
amplified by engaging the intrinsic (mitochondrial) pathway
[15]. In this context, caspase-8 cleaves Bid to generate
an active tBid, which in turn activates proapoptotic
Bax or Bak proteins, and induces mitochondrial outer
membrane permeabilization (MOMP). The mitochondria
then release proapoptotic factors that promote effector
caspases activation.
Several reports have shown that OPG is a survival factor
that can block TRAIL-induced apoptosis in tumor cells.
Human prostate cancer cells were shown to secrete OPG
at concentrations sufficient to inhibit TRAIL-induced
apoptosis in vitro [16,17]. Similarly, multiple myeloma
cells were protected from TRAIL-induced apoptosis by
OPG secreted from osteoblast-like cells and bone marrow
stroma cells [18]. OPG produced by breast cancer cells en-
hances tumor cell survival in vitro and in vivo by inhibit-
ing TRAIL-induced apoptosis [19-22]. The production of
OPG in colorectal cancer cells and the addition of exogen-
ous OPG to colorectal cancer cells both caused resistance
to TRAIL-induced apoptosis [23]. Exogenous addition of
OPG also mediates resistance to TRAIL-induced apoptosis
in ovarian cancer cells [24].
Because OPG binds to TRAIL, OPG-mediated protection
from TRAIL in various cancer cells has been assumed
to be mainly related to its decoy function. However, the
observations that OPG activates integrin/focal adhesion
kinase (FAK)/ERK1/2 signaling in endothelial cells [7,8] to
promote proliferation and migration suggest that OPG
regulates cell function directly. Indeed, it was suggested that
OPG-mediated proliferation and migration of endothelial
cells occurs in a TRAIL-independent manner [7,25]. In
ovarian cancer cells, activation of integrin/FAK and ERK1/2
signaling contribute to attenuate TRAIL-induced apoptosis
[26,27]. Based on these observations, we hypothesize
that OPG might attenuate TRAIL-induced apoptosis in a
TRAIL binding-independent manner by activating survival
signaling pathways in ovarian cancer cells. The purpose of
this study was to investigate whether exogenous OPG can
confer protection against TRAIL-induced apoptosis inde-
pendent from its ability to act as a TRAIL decoy receptor.
Results
OPG attenuates TRAIL-induced apoptosis in a TRAIL
binding-independent manner
To assess the hypothesis that OPG attenuates TRAIL-
induced apoptosis in a TRAIL binding-independentmanner, ovarian cancer cell lines CaOV3 and OVCAR3
were challenged with exogenous OPG for 1 h, washed
extensively and incubated in medium containing TRAIL.
OVCAR3 is an ovarian carcinoma cell line isolated from
malignant ascites that is resistant to clinically relevant
concentrations of cisplatin but remains sensitive to TRAIL-
induced apoptosis. CaOV3 is also an ovarian carcinoma cell
line isolated from a patient with advanced disease. The
TRAIL signaling cascade has been well characterized in
these cell lines [26-28]. The concentration of OPG was se-
lected based on our previous study, which demonstrated
that OPG, at a concentration of 25 ng/ml, significantly
attenuates TRAIL-induced apoptosis [24]. OVCAR3 and
CaOV3 cells were thus incubated with OPG for 1 h and
cells were extensively washed to remove any OPG. Cells
were then incubated in fresh medium containing TRAIL
(50 ng/ml) for 48 h. Cell viability was assessed by clono-
genic survival assays. Preincubation with OPG significantly
increased the number of viable colonies in both CaOV3
(Figure 1A) and OVCAR3 (Figure 1B) cells when compared
to cells that were not challenged with OPG before being
treated with TRAIL (P < 0.01). In agreement with these
findings, preincubation with OPG followed by its removal
before cells were challenged with TRAIL attenuated
TRAIL-induced apoptosis, as measured by oligosomal
DNA fragmentation, in both CaOV3 and OVCAR3 cells
(Figure 1C). To confirm the biological relevance these
findings, primary OC tumor cells isolated from malignant
ascites (OVC238A) were preincubated with OPG for
1 h, washed, and challenged with TRAIL. As shown in
Figure 1D, OPG significantly attenuated TRAIL-induced
apoptosis in these tumor cells (P < 0.001). To ensure that
the amount of endogenous OPG secreted by CaOV3,
OVCAR3 and OVC238A did not contribute to inhibit
TRAIL-induced apoptosis, we measured the levels of OPG
in conditioned medium from these cells. As shown in
Figure 1E, the levels of OPG secreted in conditioned
medium were below 1 ng/ml whereas the concentration of
OPG required to provide TRAIL protection is ≥ 10 ng/ml
in ovarian cancer cells [24]. All together, these data suggest
that OPG may attenuate TRAIL-induced apoptosis inde-
pendently from its decoy receptor action on TRAIL.
OPG attenuates TRAIL-induced apoptosis through an
integrin-dependent pathway
OPG-induced endothelial cell proliferation and migration
was shown to be mediated by both αvβ3 and αvβ5 integrin
suggesting that OPG may activate cell signaling [7].
Interestingly, we previously showed that signaling through
αvβ5 integrin attenuated TRAIL-induced apoptosis in OC
cells [26]. Because these data suggest that integrins might
be involved in OPG-mediated inhibition of TRAIL-induced
apoptosis in ovarian cancer cells, we examined the effect

























































































































































































































Figure 1 OPG attenuates TRAIL-induced apoptosis in a TRAIL binding-independent manner. CaOV3 cells (A) and OVCAR3 cells (B) were
preincubated for 1 h with OPG (25 ng/ml), washed extensively to remove any OPG, and treated with TRAIL (50 ng/ml) for 48 h. The cells were
then washed, seeded at different densities and incubated in fresh medium. Viable colonies were counted after 14 days and data were expressed
at fold increase relative to control (untreated) cells. Results are from three independent experiments and express as mean fold increase ± SD.
* P < 0.01 compared to control. CaOV3 and OVCAR3 cells (C) and primary tumor cells OVC238A (D) were preincubated for 1 h with OPG
(25 ng/ml), washed and incubated with TRAIL (50 ng/ml) for 24 h, and apoptosis was assessed. Apoptosis is expressed as fold increase relative to
control (untreated) cells with the mean of triplicates from three independent experiments ± SD. * P < 0.01; ** P < 0.001. (E) Concentration of OPG
released in conditioned medium from CaOV3, OVCAR3 and OVC238A cells measured by ELISA.
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express both αvβ3 and αvβ5 integrin [26], were incubated
with anti-integrin blocking antibodies for 1 h followed
by addition of OPG for 1 h. Cells were washed and TRAIL
was added. As shown in Figure 2A, pre-incubation with
αvβ3 or αvβ5 blocking antibodies significantly (P < 0.01)
reduced the protective effect of OPG on TRAIL-induced
apoptosis. The maximal reduction of OPG protection
however was observed when both blocking antibodies
were added together (Figure 2A).
The engagement of integrin to its ligand triggers a
signaling cascade that leads to the activation of FAK,
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Figure 2 Involvement of integrin/FAK signalling in OPG-mediated
protection from TRAIL. (A) CaOV3 cells were incubated with αvβ3
and αvβ5 integrin blocking antibodies (5 μg/ml) for 1 h. Cells were
washed and incubated with OPG (25 ng/ml). After 1 h, cells were
washed and TRAIL (50 ng/ml) was added for 24 h and apoptosis was
assessed. Apoptosis is expressed as fold increase relative to control
(untreated) cells with the mean of triplicates from three independent
experiments ± SD. (B) CaOV3 cells were incubated with 25 ng/ml OPG
for 1 h. Cells were lysed and subjected to immunoblotting to detect
total and phosphorylated FAK. Densitometric quantification of
phosphorylated FAK from three separate experiments normalized to
total FAK was performed.[29]. Consistent with the role of integrin in OPG-mediated
attenuation of TRAIL-induced apoptosis, we found that
FAK was phosphorylated when OVCAR3 and CaOV3 cells
were incubated with OPG while the levels of total FAK
remained relatively stable (Figure 2B). We also observed
a significant and stronger increase in the phosphorylation
of FAK in primary OVC238A cells treated with OPG
(Figure 2B). This could be related to the differential expres-
sion of integrins in ovarian cancer cell lines compared to
primary ovarian cancer specimens [30]. Nonetheless, these
data suggest that both αvβ3 and αvβ5 integrin signaling,
which results in FAK activation, are involved in OPG-
mediated attenuation of TRAIL-induced apoptosis.
An Akt-dependent pathway mediates OPG-induced
attenuation of TRAIL-induced apoptosis
Because activation of Akt pathway has been closely
correlated with TRAIL resistance in ovarian cancer cells
[15,26,31] and it is well documented that activation of
integrin/FAK signaling may lead to Akt activation [26,29],
OPG-mediated activation of Akt was evaluated. The results
show that OPG induces a dose-dependent Akt phosphoryl-
ation in CaOV3 cells (Figure 3A). OPG induces a rapid
phosphorylation of Akt that reaches a peak after 30 min
and Akt phosphorylation remained stable for up 120 min
(Figure 3B). In concert with these results, OPG treatment
of OVCAR3 and OVC238A tumor cells also induces Akt
phosphorylation (Figure 3C). Not surprisingly, OPG also
induced a dose-dependent activation of ERK in CaOV3
cells (Figure 3D). To further examine the link between
OPG-mediated Akt activation and TRAIL attenuation, we
used chemical inhibitors to block the activation of the Akt
signaling. CaOV3 cells were treated with PI3K inhibitor
(LY294002) or specific Akt inhibitor (Akt 1/2 inhibitor)
for 1 h followed by addition of OPG. After washing, TRAIL
was added and survival was evaluated by clonogenic assay.
The inhibition of PI3K/Akt signaling almost completely
abrogated the protective effect of OPG (Figure 3E). In
contrast, inhibition of ERK1/2 signaling by U0126 had no
effect on OPG-mediated protection against TRAIL-induced
apoptosis. Consistent with these findings, the inhibition of
Akt significantly abrogated OPG-mediated attenuation of
TRAIL-induced apoptosis (Figure 3F). All together, these
data suggest that Akt signaling is critical for OPG-mediated
attenuation of TRAIL-induced apoptosis while ERK signal-
ing does not play a significant role.
OPG-mediated Akt activation is regulated by
integrin/FAK signaling
Akt has been described as a downstream signaling medi-
ator for integrin/FAK-mediating event [29]. Akt activation
has also been shown to inhibit TRAIL-induced apoptosis
in ovarian cancer cells [26,31]. To determine the whether






























































































































































































Figure 3 OPG attenuates TRAIL-induced apoptosis in an Akt-dependent manner. CaOV3 cells were treated with increasing concentrations
(0–100 ng/ml) of OPG (A) or with 25 ng/ml OPG for various times (0–180 min) (B). Cells were lysed, and the levels of total and phosphorylated
Akt were determined by immunoblot. Densitometric quantification of phosphorylated Akt from three separate experiments normalized to total
Akt was done. (C) OVCAR3 and OVC238A cells were treated with 25 ng/ml OPG and 60 min later, cells were lysed and immunoblot was
performed to determine the levels of total and phosphorylated Akt. (D) CaOV3 cells were treated with increasing concentrations (0–25 ng/ml) of
OPG and total and phosphorylated ERK1/2 were determined by immunoblot. The levels of phosphorylated ERK1/2 were determined by
densitometric quantification. (E) CaOV3 cells were preincubated with LY294002 (5 uM) or Akt inhibitor (10 uM) for 1 h. OPG (25 ng/ml) was then
added for 90 min. Cells were washed and TRAIL (50 ng/ml) was added for 48 h. Viable colonies were counted after 14 days and data were
expressed at fold increase relative to control (untreated) cells. Results are from three independent experiments and express as mean fold increase ± SD.
(F) CaOV3 cells were preincubated for 1 h with either Akt or ERK1/2 inhibitor and OPG (25 ng/ml) was added for 90 min. Cells were washed and
incubated with TRAIL (50 ng/ml) for 24 h, and apoptosis was assessed. Apoptosis is expressed as fold increase relative to control (untreated) cells with
the mean of triplicates from three independent experiments ± SD. * P < 0.01 compared to TRAIL + OPG treated cells; ** P < 0.001.
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on Akt and ERK1/2 activation in CaOV3 cells. Cells were
incubated with anti-integrin blocking antibodies for 1 h,
stimulated with OPG for 1 h and cell lysates were assayed
by immunoblot for Akt activation. OPG-mediated Aktactivation was markedly decreased by αvβ3 or αvβ5 block-
ing antibodies or a combination of both (Figure 4A). In
contrast, OPG-mediated activation of ERK1/2 was un-
affected by αvβ3 or αvβ5 blocking antibodies or the
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Figure 4 Integrin/FAK mediates OPG-induced Akt activation. CaOV3 cells were incubated with αvβ3 and αvβ5 integrin blocking antibodies
(5 μg/ml) for 1 h. Cells were washed, incubated with OPG (25 ng/ml) for 90 min and subsequently lysed for immunoblot with (A) anti-Akt and
anti-phospho-Akt antibodies or (B) anti-ERK1/2 or anti-phospho-ERK1/2 antibodies. Densitometric quantification of phosphorylated Akt from three
separate experiments normalized to total Akt was done. (C) CaOV3 cells were treated with either lipid vehicle alone, non-targeted siRNA
(NT siRNA) or FAK siRNA for 24 h. OPG (25 mg/ml) was then added for 90 min and cells were subsequently lysed and immunoblotted for total
FAK, phosphorylated FAK, total Akt and phosphorylated Akt. (D) CaOV3 cells were preincubated for 24 h with either lipid vehicle alone,
non-targeted siRNA (NT siRNA) or FAK siRNA. OPG (25 ng/ml) was then added for 90 min. Cells were washed and incubated with TRAIL
(50 ng/ml) for 24 h, and apoptosis was assessed. Apoptosis is expressed as fold increase relative to control (untreated) cells with the mean of
triplicates from three independent experiments ± SD. * P < 0.01, ** P < 0.001 compared to NT siRNA treated cells.
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was down-regulated using a FAK siRNA, and Akt activa-
tion was assessed by immunoblot. siRNA-mediated down-
regulation of FAK strongly inhibited Akt phosphorylation
in OPG-stimulated CaOV3 cells (Figure 4C). To further
define the contribution of FAK to OPG-mediated attenu-
ation of TRAIL-induced apoptosis, CaOV3 cells were
pre-incubated with OPG, washed and treated with TRAIL
in the presence of control (NT siRNA) or FAK siRNA
(Figure 4D). The down-regulation of FAK expression
significantly inhibited the prosurvival effect of OPG.
The data suggest that Akt is activated by OPG via αvβ3
or αvβ5 integrins/FAK signaling.Discussion
Important aspects of ovarian cancer progression include
resistance to drug-induced apoptosis. Early studies have
shown that OPG, in paracrine or autocrine manners,
functions as a survival factor for tumor cells by preventing
apoptosis induced by TRAIL [16-23]. Indeed, soluble se-
creted OPG has been shown to act as a decoy receptor
for TRAIL [11,12]. In addition, OPG has been shown to
promote angiogenesis and endothelial cell migration and
proliferation by inducing integrin signaling [7-10]. Recent
studies have also demonstrated that αvβ5 integrin/Fak
signaling attenuates TRAIL-induced apoptosis in ovarian
cancer cells by activating Akt survival pathway [26]. These
Lane et al. Journal of Ovarian Research 2013, 6:82 Page 7 of 9
http://www.ovarianresearch.com/content/6/1/82findings prompted us to investigate whether OPG can
protect ovarian cancer cells in a TRAIL-binding inde-
pendent manner. In the present study, we found that
OPG attenuates TRAIL-induced apoptosis independ-
ently from its binding to TRAIL. Indeed, incubation of
ovarian cancer cells with exogenous OPG, followed by
removal of OPG and treatment with TRAIL significantly
inhibited TRAIL-induced apoptosis (Figure 1), suggesting
that OPG may attenuates TRAIL-induced apoptosis via
TRAIL binding-dependent and -independent mechanisms.
Previous studies have shown that OPG rapidly activates
integrin/FAK signaling in endothelial cells and that OPG-
mediated integrin signaling is strongly inhibited by αvβ3
and αvβ5 integrin blocking antibodies [7,8]. Similarly, we
showed that OPG activates both αvβ3 and αvβ5 integrin
signaling in ovarian cancer cells (Figure 2). These findings
suggest that OPG-induced integrin/FAK signaling may be
common in all OPG-responsive cell types. In addition, the
fact that both OPG and malignant ascites activate integ-
rin/FAK signaling and attenuate TRAIL-induced apoptosis
suggest that integrin signaling is central to protect ovarian
cancer cells from TRAIL cytotoxicity. Several recent studies
have shown that Akt activation is important for ovarian
cancer cell survival [15,26,31,32]. In this study, we found
that OPG-induced attenuation of TRAIL-induced apoptosis
was significantly inhibited by chemical inhibitors of the
PI3K/Akt pathway (Figure 3) and that OPG activates Akt in
an integrin/FAK-dependent manner in ovarian cancer cells
(Figure 4). Furthermore, although ERK1/2 was rapidly acti-
vated by OPG, experiments with ERK1/2 inhibitors showed
that ERK1/2 activation was not required for OPG-induced
attenuation of TRAIL-induced apoptosis (Figure 3).
Akt may be activated by various mechanisms, including
growth factor receptors, cytokine receptors and G-protein
coupled receptors [33]. However, we found that αvβ3
and αvβ5 integrin blocking antibodies and siRNA-
mediated downregulation of FAK almost completely
abolish OPG-mediated Akt activation. Therefore, we
conclude that integrin/FAK signaling is the main path-
way involved in OPG-mediated Akt activation. This is
consistent the recent study showing that inhibition of
growth factor receptors and G-protein coupled recep-
tors failed to block ascites-induced Akt activation in
ovarian cancer cells [26]. The inhibition of αvβ5 integrin/
FAK signaling however resulted in the blockade of Akt
activation in that study.
In conclusion, we have demonstrated that the αvβ3
and αvβ5 integrin/FAK/Akt pathway is involved in
OPG-induced attenuation of TRAIL-induced apoptosis
in ovarian cancer cells. Furthermore, the present study
provides novel information about the mechanisms by
which OPG attenuates TRAIL-induced apoptosis by
demonstrating that OPG acts also in a TRAIL binding-
independent manner.Methods
Primary tumor cells and cell lines
The study was approved by the institutional review board
of the Centre Hospitalier Universitaire de Sherbrooke.
Written informed consent was obtained from the patient
for the publication of this report and any accompaying
images from women that undergone surgery by the gyneco-
logic oncology service for OC. Primary tumor cells isolated
from malignant ovarian cancer ascites were supplied by the
Banque de tissus et de données of the Réseau de Recherche
en Cancer of the Fonds de la Recherche du Québec
en Santé (FRQS) affiliated with the Canadian Tumor
Repository Network (CTRNet). Primary tumor cells
(OVC238A) were isolated as follow: ovarian cancer ascites
were centrifuged at 1000 rpm for 15 min and cells were
washed twice with OSE medium (Wisent, St-Bruno,
Québec, Canada). Cells were then resuspended in OSE
medium supplemented with 10% FBS, β-estradiol (10-8 M),
2 mM glutamine, antibiotics and fungizone and plated into
75 cm2 flasks. All floating cells were removed the next
day. Tumor cell samples were used at low passage (< 10).
Primary tumor cells (OVC238A) were obtained from
patients with advanced serous OC. These cells have been
previously described and stained positive for epithelial
tumor markers anti-CA125 and cytokeratine 8/18 and
negative for fibroblast specific marker fibroblast antigen
[24]. The OC cell lines CaOV3 and OVCAR3 were obtained
from American Type Culture Collection, (Manassas, VA)
and maintained in a humidified 5% CO2 incubator at
37°C. Cells were passaged twice weekly. OVCAR3 cells
were maintained in RPMI-1640 (Wisent, St-Bruno, QC,
Canada) supplemented with 20% FBS, insulin (10 mg/L),
glutamine (2 mM) and antibiotics. CaOV3 cells were
cultured in DMEM/F12 (Wisent) supplemented with
10% FBS, 2 mM glutamine and antibiotics.
Reagents
Recombinant human TRAIL was purchased from
PeproTech (Rocky Hill, NJ). Recombinant OPG was
purchased from R&D Systems (Mineapolis, MN). OPG
ELISA was purchased from eBioscience (Vienna, Austria).
Antibodies for Akt and FAK were from Cell Signaling.
Antibodies for phospho-Akt (Ser-473) and phospho-FAK
(Tyr-397) were form Life Technologies (Burlington,
ON, Canada). ERK antibody was from Santa Cruz Biotech
(Santa Cruz, CA). Integrin-blocking antibodies anti-
αvβ3 (clone LM609) and anti- αvβ5 (clone PF16) were
from Millipore (Temecula, CA). Anti-tubulin antibody
was obtained from Sigma (Oakville, ON, Canada).
Akt inhibitor 1/2 (1 L-6-hydroxymethyl-chiro-inositol
2(R)-2-O-methyl-3-O-octadecylcarbonate) was from
Calbiochem (San Diego, CA). PI3K inhibitor LY294002
and MEK inhibitor U0126 was purchased from EMD
(Billerica, MA).
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For clonogenic survival assays, cells were plated into
25 cm2 tissue culture plates in standard medium. The next
day, cells were incubated for 90 min in medium containing
OPG (25 ng/ml). Cells were then extensively washed to
remove any OPG and TRAIL (50 ng/ml) was added to
fresh medium for 48 h. Cells were then washed with PBS
and incubated in fresh medium into 6-well plates at
the different densities for 14 days. Cells were fixed and
stained with crystal violet. The number of colonies,
consisting of > 50 cells, in triplicate was counted.
Conditioned medium
Once cells have reached confluence, the medium was
removed and fresh medium was added. After 48 h, the
conditioned medium was removed, centrifuged and stored
at −20°C until used.
Apoptosis
Cells were incubated in medium containing OPG (25 ng/ml)
for 1 h. Cells were washed to remove OPG and TRAIL
(50 ng/ml) was added to fresh medium for 24 h. The release
of nucleosomal DNA into the cytoplasm as a measure of
apoptosis was determined using the Cell Death Detection
ELISA Kit (Roche, Laval, Québec, Canada) according to the
manufacturer’s instruction. The absorbance was determined
using a microplate reader at 410 nm.
siRNA transfection
The FAK and non-targeted (NT) siRNA oligonucleotides
were purchased from Dharmacon Research Inc (Ottawa,
ON, Canada). Cells were seeded in six-well plates and
allowed to adhere for 24 h. Cells (50% confluent) were
transfected with a mixture containing Lipofectamine 2000
(Life Technology), OPTIMEM (Life Technology) and
siRNA. The siRNA/Lipofectamine complex was then added
to the medium. The final concentration of siRNA was
10 mM. Cells were incubated for 4–6 h at 37°C and
fresh medium was then added.
Statistical analysis
Experiments were performed in triplicate, and data pre-
sented as mean ± SD. Student’s paired t-test was used to
analyze differences between the treatment conditions
and their controls. The threshold for statistical significance
is P < 0.05.
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